Peficitinib
Chemical compound
- L04AF06 (WHO)
- In general: ℞ (Prescription only)
- 944118-01-8
- 57928403
- HPH1166CKX
- D10721
- Interactive image
- NC(=O)c1cnc2[nH]ccc2c1NC1[C@H]2CC3C[C@@H]1CC(O)(C3)C2
InChI
- InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,1 Y
- Key:DREIJXJRTLTGJC-JQCLMNFQSA-N Y
Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).[1][2]
Peficitinib was approved for use in Japan in 2019.[3]
References
- ^ Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi:10.1002/art.39955. PMID 27748083.
- ^ Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi:10.1002/art.40054. PMID 28118538.
- ^ Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.
- v
- t
- e
Cytokine receptor modulators
- See here instead.
Erythropoietin |
|
---|---|
G-CSF (CSF3) |
|
GM-CSF (CSF2) |
|
M-CSF (CSF1) |
|
SCF (c-Kit) |
|
Thrombopoietin |
|
IFNAR (α/β, I) |
|
---|---|
IFNGR (γ, II) |
|
IFNLR (λ, III) |
|
- See here instead.
- See here instead.
- See here instead.
JAK (inhibitors) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Others |
|
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e